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Background: The ECL2 of the GLP-1R is critical for GLP-1 peptide-mediated selective signaling.
Results: Mutation of most ECL2 residues to alanine results in changes in binding and/or efficacy of oxyntomodulin and
exendin-4 but not allosteric agonists.
Conclusion: ECL2 of the GLP-1R has ligand-specific as well as general effects on peptide agonist-mediated receptor activation.
Significance: This work provides insight into control of family B GPCR activation transition.
The glucagon-like peptide-1 receptor (GLP-1R) is a prototyp-
ical family B G protein-coupled receptor that exhibits physio-
logically important pleiotropic coupling and ligand-dependent
signal bias. In our accompanying article (Koole, C.,Wootten,D.,
Simms, J., Miller, L. J., Christopoulos, A., and Sexton, P. M.
(2012) J. Biol. Chem. 287, 3642–3658), we demonstrate, through
alanine-scanning mutagenesis, a key role for extracellular loop
(ECL) 2 of the receptor in propagating activation transition
mediated by GLP-1 peptides that occurs in a peptide- and path-
way-dependent manner for cAMP formation, intracellular
(Ca2i) mobilization, and phosphorylation of extracellular sig-
nal-regulated kinases 1 and 2 (pERK1/2). In this study, we exam-
ine the effect of ECL2mutations on the binding and signaling of
the peptide mimetics, exendin-4 and oxyntomodulin, as well as
small molecule allosteric agonist 6,7-dichloro-2-methylsulfo-
nyl-3-tert-butylaminoquinoxaline (compound 2). Lys-288, Cys-
296, Trp-297, and Asn-300 were globally important for peptide
signaling and also had critical roles in governing signal bias of
the receptor. Peptide-specific effects on relative efficacy and sig-
nal bias were most commonly observed for residues 301–305,
although R299A mutation also caused significantly different
effects for individual peptides.Met-303 wasmore important for
exendin-4 and oxyntomodulin action than those of GLP-1 pep-
tides. Globally, ECL2 mutation was more detrimental to exen-
din-4-mediated Ca2i release than GLP-1(7–36)-NH2, provid-
ing additional evidence for subtle differences in receptor
activation by these two peptides. Unlike peptide activation of
the GLP-1R, ECL2 mutations had only limited impact on com-
pound 2 mediated cAMP and pERK responses, consistent with
this ligand having a distinct mechanism for receptor activation.
These data suggest a critical role of ECL2 of the GLP-1R in the
activation transition of the receptor by peptide agonists.
The family B GPCR,3 GLP-1R, is an important target for
the treatment of type II diabetes mellitus, and it has multiple
endogenous ligands, including four forms of GLP-1, plus the
related peptide oxyntomodulin (1, 2). Therapeutically, the
mimetic peptide exendin-4 and metabolically stabilized forms
of GLP-1 have recently been approved for treatment of type II
diabetes mellitus (3, 4), although an oxyntomodulin derivative
is also in clinical trials. In addition, there are a number of small
molecule agonists/modulators that can augment responses via
the GLP-1R (5–8), including the Novo Nordisk compound 2
(6). Exendin-4 is believed to closely mimic the actions of GLP-
1(7–36)-NH2 at the receptor, but oxyntomodulin and the small
molecule ligand, compound 2, display biased signaling relative
to the truncated GLP-1 peptides (5, 6, 9). The molecular basis
for these distinct actions is not known. Nonetheless, there is
accumulating evidence that ECLs, in particular ECL2, may be
important for peptide-mediated activation of family B GPCRs
(10–17).
In our accompanying article (18), we demonstrate that indi-
vidual amino acids within ECL2 play a critical role in the acti-
vation transition linking GLP-1 peptide binding to intracellular
signaling (18) and that it is intimately linked to conformational
control of signal bias initiated by peptide binding. However,
peptide-specific differences in the effect of ECL2 mutations
were also observed between GLP-1(1–36)-NH2 and GLP-1(7–
36)-NH2 consistent with the ability of ECL2 to contribute to
peptide-selective signal bias.
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In this study,wehave further explored the functionofECL2and
adjacentdomainsof thehumanGLP-1R throughpharmacological
characterization of the alanine-scanning mutants of ECL2 in the
presence of the exogenousGLP-1 peptidemimetic exendin-4, the
endogenous peptide agonist oxyntomodulin, or the allosteric ago-
nist compound 2. We demonstrate that select ECL2 residues are
critically involved in oxyntomodulin and exendin-4 binding and
receptor activity, while also showing that ECL2 has little influence
on compound 2 binding and activity, consistent with small mole-
cule agonists having a distinct mode of action.
EXPERIMENTAL PROCEDURES
Materials—Compound 2 was generated in our laboratory,
according to the method published previously (19), to a purity
of 95%, and compound integrity was confirmed by NMR.
Exendin-4 and oxyntomodulin were purchased fromAmerican
Peptide (Sunnyvale, CA).All other reagentswere obtained from
suppliers as described in the accompanying article (18).
Methods—Receptor mutagenesis, cell transfection and cell
culture, measurement of cell surface expression by antibody
labeling of the c-Myc epitope, radioligand binding assays,
cAMP accumulation, pERK1/2, and Ca2i mobilization assays
were each performed as described in our accompanying article
(18). For pertussis toxin pretreatment experiments, cells were
cultured in FBS-free DMEM containing 100 ng ml1 pertussis
toxin and incubated overnight at 37 °C in 5% CO2. Data for
these experiments were normalized to the maximal response
elicited by peptide alone. All other data normalization was per-
formed as described in our accompanying article (18).
Data analysis for determination of IC50, EC50, and opera-
tional measures of efficacy was performed as described in our
accompanying article (18).
Statistics—Changes in ligand affinity, potency, efficacy, and
cell surface expression of ECL2 mutants in comparison with
wild type control were statistically analyzed with one-way anal-
ysis of variance and Dunnett’s post test, and significance was
accepted at p 0.05.
RESULTS
Cell Surface Expression of Human GLP-1R ECL2 Alanine
Mutants—As reported in our accompanying article (18), cell sur-
face expression determined through detection of the N-terminal
double c-Myc epitope label was reduced for mutant receptors
D293A, C296A,W297A, S301A, N304A, Y305A, and L307A, and
it increased for N300A and M303A, although no significant
changes were observed for the remaining mutants (Table 1). In
most cases, specific binding of 125I-exendin(9–39) followed the
same trend as antibody labeling. The exceptions to this were
E294A andT298A that had increased specific 125I-exendin(9–39)
binding in comparison with wild type control, but decreased or
unchanged cell surface antibody labeling, and R299A that had
decreased specific 125I-exendin(9–39) binding but unaltered cell
surface antibody labeling. TheW306Amutant, however, was not
expressed at all at the cell surface andwill not bedescribed further.
Select Mutants of the Human GLP-1R ECL2 Influence
Exendin-4 and Oxyntomodulin Binding Affinity but Not
Exendin(9–39) Affinity—Affinity of exendin-4 and oxynto-
modulin at each of themutants was assessed by competition for
125I-exendin(9–39) binding under equilibrium conditions
(Table 1). There were no significant changes in binding affinity
of exendin-4 or oxyntomodulin in comparison with the wild
type control for receptor mutants G285A, I286A, V287A,
Y289A, L290A, Y291A, E294A, G295A, T298A, S301A, and
N304A, although decreases in affinity for both ligands were
observed for receptor mutants K288A, E292A, D293A, C296A,
W297A, R299A, N300A, N302A, M303A, Y305A, and L307A,
TABLE 1
Effects of human GLP-1R ECL2 alanine mutants on peptide ligand
binding and cell surface expression
Binding data were analyzed using a three-parameter logistic equation as defined in
Equation 1 of the accompanying article. pIC50 values were then corrected for radio-
ligand occupancy using the radioligand dissociation constant for each mutant,
allowing determination of ligand affinity (Ki). All values are expressed as means 
S.E. of three to four independent experiments, conducted in duplicate. Data were
analyzed with one-way analysis of variance and Dunnett’s post test. R2 values for
curve fits were all 0.5. Gray shading highlights residues effecting peptide agonist
binding affinity. ND indicates data unable to be experimentally defined.
* Data are statistically significant at p 0.05, one-way analysis of variance, and
Dunnett’s post test in comparison with wild type response.
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as highlighted in gray in Table 1 (Fig. 1, B–E, and Table 1). This
shading is maintained throughout all tables as an indication of
mutants affected in binding affinity. Curves could not be accu-
rately fitted for C296A and W297A in the presence of oxynto-
modulin, most likely a result of the narrow window of signal
generated by the significant decrease in specific 125I-
FIGURE 1. Agonist binding profiles of human GLP-1R ECL2 alanine mutants. A, schematic representation of the human GLP-1R ECL2, with disulfide
interactions indicated (—) and boundaries indicated in gray shading. Characterization of the binding of exendin-4 (B and C) and oxyntomodulin (D and E) is in
competitionwith the radiolabeledantagonist, 125I-exendin(9–39), inwhole FlpInCHOcells stably expressing thewild typehumanGLP-1Ror eachof thehuman
GLP-1R ECL2 alanine mutants that effect peptide binding affinity or the wild type GLP-1R. Data are normalized tomaximum 125I-exendin(9–39) binding, with
nonspecific binding measured in the presence of 1 M exendin(9–39) and analyzed with a three-parameter logistic equation as defined in Equation 1 of the
accompanying article. All values are means S.E. of three to four independent experiments, conducted in duplicate.
ECL2 Differentially Controls Agonist Activation of GLP-1Rs
FEBRUARY 3, 2012•VOLUME 287•NUMBER 6 JOURNAL OF BIOLOGICAL CHEMISTRY 3661
 at A
STO
N
 U
N
IV
ERSITY
 on Septem
ber 5, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
exendin(9–39) binding (Table 1 of Ref. 18). In addition, binding
affinity could not be determined for oxyntomodulin at mutant
receptors R299A and Y305A due to incomplete curves,
although reductions in binding affinity were apparent (Fig. 1).
Notably, although the extent of affinity reduction of exendin-4
and oxyntomodulin was generally similar, differential effects of
mutation were observed for the K288A, E292A, and N300A
mutants with decreases in binding affinity of 79-, 63-, and
63-fold, respectively, for exendin-4, but only 10-, 16-, and
10-fold, respectively, for oxyntomodulin (Table 1).
Effect of Human GLP-1R ECL2 Alanine Mutations on Pep-
tide-mediated cAMP Accumulation—The effect of mutation
on ligand-induced cAMP formation was assessed via determi-
nation of potency and efficacy; the latter was estimated using an
operational model corrected for receptor expression (c, Table
2). Although both peptides were full agonists, exendin-4 had
higher efficacy than oxyntomodulin in this system (logc 1.03
0.09 and 0.83  0.07, respectively). With the exception of the
M303Amutant, all mutants with reduced peptide agonist bind-
ing displayed reduced potency and efficacy, although the exen-
din-4 potency shift for R299A did not reach significance (Fig. 2,
A, B, E, and F, and Table 2). The greatest effects on cAMP
formation, for both peptides, were seen with the K288A and
W297Amutants, with signaling essentially abolished at K288A
and complete loss of oxyntomodulin signaling and marked
attenuation of exendin-4 potency and efficacy atW297A (Fig. 2,
A, B, E, and F, and Table 2). Similar reductions in responses
elicited by both peptides were seen for the D293A, R299A,
N302A, Y305A, and L307A mutants. In contrast, E292A,
C296A, and N300A showed greater relative loss of exendin-4
potency, compared with that of oxyntomodulin with fold
decreases in potency of 126, 100, and 316, respectively, for
exendin-4 and 25, 32, and 20, respectively, for oxyntomodulin.
This differential effect on potency was paralleled by greater
decreases in binding affinity of exendin-4 for E292A and
N300A, although the magnitude of effect on C296A affinity for
oxyntomodulin could not be accurately determined (see
above). Interestingly, at these mutants there was a correspond-
ingly greater reduction in efficacy for oxyntomodulin relative to
exendin-4, illustrating distinction in the impact of these resi-
dues on oxyntomodulin and exendin-4 function (Fig. 2, A and
B, and Table 2).
TABLE 2
Effects of human GLP-1R ECL2 alanine mutants on peptide agonist signaling via cAMP
Data were analyzed using a three-parameter logistic equation as defined in Equation 1 of the accompanying article. pEC50 values represent the negative logarithm of the
concentration of agonist that produces half the maximal response. Emax represents the maximal response normalized to that elicited by 100M forskolin. All mutants were
analyzed with an operational model of agonism (Equation 2 of the accompanying article) to determine log values. All log values were then corrected to specific 125I-
exendin(9–39) binding (logc). Values are expressed as means S.E. of three to seven independent experiments, conducted in duplicate. Data were analyzed with one-way
analysis of variance and Dunnett’s post test. R2 values for the global curve fits were 0.87 for exendin-4 and 0.91 for oxyntomodulin, respectively. Gray shading highlights
residues effecting peptide agonist binding affinity. ND indicates data unable to be experimentally defined.
* Data are statistically significant at p 0.05, one-way analysis of variance, and Dunnett’s post test in comparison with the wild type response.
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For those mutants that did not affect peptide binding, the
effect on cAMP signaling was similar for both peptides.
None of the mutants significantly altered potency of the
peptides, although efficacy was also unaltered for the
G285A, I286A, and G295A mutants (Fig. 2, C–F, and Table
2). All other mutants exhibited modest decreases in efficacy
for the two peptides, although the effects did not always
reach significance. The greatest effects on efficacy were seen
with the S301A and N304A mutants (Fig. 2, E and F, and
Table 2).
FIGURE 2. cAMP accumulation profiles of human GLP-1R ECL2 alanine mutants. Characterization of cAMP accumulation in the presence of exendin-4 (A
and C) and oxyntomodulin (B andD) in FlpInCHO cells stably expressing thewild type human GLP-1R or each of the human GLP-1R ECL2 alaninemutants that
effect peptide binding affinity (A and B) or have no significant effect on peptide binding affinity (C andD). Data are normalized to the response elicited by 100
M forskolin and analyzed with an operational model of agonism as defined in Equation 2 of the accompanying article. All values are means S.E. of three to
seven independent experiments, conducted in duplicate. Visual representation of cAMPpathway coupling efficacy (logc) in the presence of exendin-4 (E) and
oxyntomodulin (F) is shown. Statistical significance of changes in coupling efficacy in comparison with wild type human GLP-1R was determined by one-way
analysis of variance and Dunnett’s post test, and values are indicated with an asterisk (*, p 0.05). All values are logc S.E. of three to seven independent
experiments, conducted in duplicate.
ECL2 Differentially Controls Agonist Activation of GLP-1Rs
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Effect of Human GLP-1R ECL2 Alanine Mutations on Pep-
tide-mediated pERK1/2—Peptide-inducedpERK1/2was deter-
mined at 6 min for each of the human GLP-1R ECL2 alanine
mutants. As noted in our accompanying article (18) for GLP-1(7–
36)-NH2, ECL2 mutations globally had a lower impact on
pERK1/2 relative to cAMP formation. There was also a gen-
erally greater impact on oxyntomodulin-induced signaling
relative to that of exendin-4 (Fig. 3, A, B, E, and F, and Table
3). Only K288A had any effect on peptide potency, with
decreased exendin-4 potency and a trend toward decreased
FIGURE3.pERK1/2profilesofhumanGLP-1RECL2alaninemutants.Characterizationof pERK1/2 in thepresenceof exendin-4 (A andC) andoxyntomodulin
(B and D) in FlpInCHO cells stably expressing the wild type human GLP-1R or each of the human GLP-1R ECL2 alanine mutants that effect peptide binding
affinity (A and B) or have no significant effect on peptide binding affinity (C and D). Data are normalized to the maximal response elicited by 10% FBS and
analyzedwith an operationalmodel of agonism as defined in Equation 2 of the accompanying article. All values aremeans S.E. of five to seven independent
experiments, conducted in duplicate. Visual representation of pERK1/2 coupling efficacy (logc) in the presence of exendin-4 (E) and oxyntomodulin (F) is
shown. Statistical significance of changes in coupling efficacy in comparison with wild type human GLP-1R was determined by one-way analysis of variance
and Dunnett’s post test, and values are indicatedwith an asterisk (*, p 0.05). All values are logc S.E. of five to seven independent experiments, conducted
in duplicate.
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potency for oxyntomodulin (Table 3). Of the other mutants
that displayed reduced exendin-4 binding affinity, none had
statistically significant effects on efficacy. For oxyntomodu-
lin, significant loss of efficacy was observed for the E292A,
D293A, N300A, N302A, and Y305A mutants. Whereas sim-
ilar trends for lower efficacy were seen for exendin-4 at most
of these mutants, Y305A efficacy was increased (Fig. 3, A, B,
E, and F, and Table 3). No significant effects on efficacy were
seen for either peptide or for the mutants that did not mod-
ulate peptide binding affinity (Fig. 3, C–F, and Table 3).
Effect of Human GLP-1R ECL2 Alanine Mutations on Pep-
tide-mediated Ca2i Mobilization—Of the three signaling
pathways studied, Ca2i mobilization is the least well coupled
and is also the one most affected by ECL2 mutations (Table 4).
For the mutations that reduced exendin-4 binding affinity
(K288A, E292A, D293A, C296A, W297A, R299A, N300A,
Y305A, andL307A), therewas effectively complete loss of exen-
din-4-mediated signaling and only weak responses for N302A
and M303A, with marked reduction in efficacy, but no signifi-
cant change in potency (Fig. 4A and Table 4). For mutants that
did not alter exendin-4 affinity, reduced efficacy was also
observed, with the exceptions being G285A, G295A, T298A,
and S301A (Fig. 4, B and C, and Table 4).
As observed previously (5, 9), oxyntomodulin has very weak
coupling to Ca2i mobilization, and full concentration-response
curves could not be established over the concentration range
assessed. Comparison of responses at the highest concentration
used (1 M) revealed reduced responses for each of the mutants
that decreased oxyntomodulin affinity (K288A, E292A, D293A,
C296A, W297A, R299A, N300A, N302A, M303A, Y305A, and
L307A) (Fig. 4D). Reduced responses were also observed for
T298AandN304A.Ofnote, no significant change in responsewas
observed for E294A, despite a significantly reduced exendin-4
response (Fig. 4, B andD).
TABLE 3
Effects of human GLP-1R ECL2 alanine mutants on peptide agonist signaling via pERK1/2
Data were analyzed using a three-parameter logistic equation as defined in Equation 1 of the accompanying article. pEC50 values represent the negative logarithm of the
concentration of agonist that produces half themaximal response. Emax represents themaximal response normalized to that elicited by 10% FBS. All mutants were analyzed
with an operational model of agonism (Equation 2 of the accompanying article) to determine log values. All log values were then corrected to specific 125I-exendin(9–39)
binding (logc). Values are expressed as means  S.E. of five to seven independent experiments, conducted in duplicate. Data were analyzed with one-way analysis of
variance and Dunnett’s post test. R2 values for the global curve fits were 0.67 for exendin-4 and 0.66 for oxyntomodulin, respectively. Gray shading highlights residues
effecting peptide agonist binding affinity. ND indicates data unable to be experimentally defined.
* Data are statistically significant at p 0.05, one-way analysis of variance, and Dunnett’s post test in comparison with wild type response.
ECL2 Differentially Controls Agonist Activation of GLP-1Rs
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Effect of Human GLP-1R ECL2 Alanine Mutations on the
Function of the GLP-1R Allosteric Agonist, Compound 2—In
addition to analyzing the effects of human GLP-1R ECL2 on
peptide agonist binding and function, we also analyzed the
effect of these mutants on binding and function of the GLP-1R
allosteric agonist, compound 2 (Fig. 5 and Table 5) (5, 6). Com-
pound 2 is a weak allosteric inhibitor of 125I-exendin(9–39)
binding (5). Mutation of ECL2 had no effect on compound 2
inhibition of the radioligand relative to the wild type receptor,
although for mutants with low specific 125I-exendin(9–39)
binding (see Table 1 of Ref. 18), the effect of the mutations on
compound 2-mediated inhibition of binding could not be
robustly determined (data not shown).
Compound 2 is a lowpotency but high efficacy partial agonist
for GLP-1R-mediated increases in cAMP formation and aweak
partial agonist for receptor-mediated pERK1/2 (5). The maxi-
mal concentration of compound 2 used in this studywas 10M,
which approaches the solubility limit of the compound.
Although previous studies suggest that this concentration elic-
its a near maximal cAMP response (5, 9), the upper plateau of
the concentration-response curve was not fully defined in this
study, preventing application of the operationalmodel fitting to
the data and determination of efficacy-related effects inde-
pendent of receptor expression. Analysis of the effect of muta-
tions on cAMP formation revealed limited impact on com-
pound 2-mediated signaling with no change to potency and
only small decreases in maximal response (Fig. 5, A and B, and
Table 5). The decreases observed in maximal response were
paralleled by decreases in functional cell surface receptor
expression (18), suggesting that this likely underlies loss of sig-
naling rather than a direct effect on receptor activation by com-
pound 2. Therewas no significant alteration to potency ormax-
imal response to compound 2-mediated pERK1/2 for any of the
ECL2 mutants (Fig. 5, C and D, and Table 5).
Human GLP-1R ECL2 Is Critical for Peptide-mediated Acti-
vation Transition of GLP-1R—Overall, there was a strong cor-
relation of the effect of the mutations on changes to efficacy for
peptide-mediated cAMP and pERK1/2, albeit that the changes
were not necessarily in the same direction, and this was partic-
ularly true for oxyntomodulin responses (Fig. 6). A lower
degree of correlation was seen between the effect of mutation
on exendin-4 between either cAMPor pERK1/2 andCa2i (Fig.
6, B and C), although this is likely related, at least in part, to the
large number of mutants without a measurable Ca2i response
to this peptide. Globally, this is consistent with a key role for
ECL2 in the generation of the ensemble of receptor conforma-
tions linked to signaling responses. The relative preservation, or
even increase, in pERK1/2 response upon ECL2 mutation rela-
tive to the other signaling pathways suggests that the ensemble
of conformations mediating pERK1/2 are quite distinct from
those linked to cAMP formation and Ca2i mobilization.
Nonetheless, although the data are consistent with amajor role
of ECL2 in conformational propagation, there were clear exam-
ples where individual mutation had pathway-selective effects
on efficacy. For oxyntomodulin, there was a very tight correla-
tion between the effect of most mutations on pERK1/2 and
cAMP efficacy. The exceptions to this were the R299A and
M303A mutants (Fig. 6D), indicating differential effects on
oxyntomodulin-mediated signaling. For the M303A mutation
this manifests as a minimal loss of cAMP signaling compared
with pERK1/2, although for the R299A mutation there was a
relatively greater loss of cAMP signaling. For exendin-4, there
was proportionally greater loss of cAMP efficacy relative to
pERK1/2 efficacy for M303A, L307A, and W297A, although
L290A exhibited relatively preserved cAMP efficacy relative to
the loss of pERK1/2 signaling. The outliers for exendin-4 and
oxyntomodulin were mostly distinct from those observed with
the GLP-1 peptides (18), although R299A, L290A, andW297A
were also among those residues that exhibited noncorrelative
effects across different pathways. For the GLP-1 peptides,
N304A also displayed pathway- and peptide-dependent effects
on efficacy, although this residue displayed mostly consistent
effects across pathways for exendin-4 and oxyntomodulin.
Thus, although ECL2 is globally important for receptor activa-
tion, individual residues likely contribute to secondary struc-
ture that is important for peptide-specific receptor activation.
TABLE 4
Effects of human GLP-1R ECL2 alanine mutants on peptide agonist
signaling via Ca2imobilization
Datawere analyzed using a three-parameter logistic equation as defined in Equation
1 of the accompanying article. pEC50 values represent the negative logarithm of the
concentration of agonist that produces half the maximal response. Emax represents
the maximal response normalized to that elicited by 100MATP. All mutants were
analyzed with an operational model of agonism (Equation 2 of the accompanying
article) to determine log values. All log values were then corrected to specific
125I-exendin(9– 39) binding (logc). Values are expressed as means S.E. of four to
five independent experiments, conducted in duplicate. Data were analyzed with
one-way analysis of variance and Dunnett’s post test. The R2 value for the global
curve fit was 0.85.Gray shading highlights residues effecting peptide agonist binding
affinity. ND indicates data unable to be experimentally defined.
* Data are statistically significant at p 0.05, one-way analysis of variance, and
Dunnett’s post test in comparison with wild type response.
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Effect of Human GLP-1R ECL2 Alanine Mutations on Pep-
tide-mediated Signal Bias—Bias plots provide a useful tool for
comparing relative bias of peptides across two pathways inde-
pendent of absolute potency (20). Visualization of signaling in
this manner revealed strong relative bias of exendin-4 for
cAMP formation relative to pERK1/2, with weaker relative bias
for pERK1/2 over Ca2i mobilization (supplemental Fig. S1,
A–C). In contrast, oxyntomodulin was only weakly biased
toward cAMP signaling relative to pERK1/2 (supplemental Fig.
S1D) but was poorly coupled to Ca2i mobilization. Whereas
most mutations had minimal effect on bias (although distinct
effects on efficacy could be distinguished), a number of muta-
tions appeared to be critically important for maintaining path-
way bias, albeit in a peptide-dependent manner (Table 6 and
supplemental Fig. S1). Asn-300 appeared to play a critical role
in maintaining pathway bias of exendin-4, oxyntomodulin, and
GLP-1(7–36)-NH2 (18) toward cAMP formation over pERK1/2
and likely has a similar influence on GLP-1(1–36)-NH2, where
cAMP formation was completely abrogated (18). For all three
peptides, there was a complete reversal of bias with this mutant
for these two pathways (supplemental Fig. S1, A and D) (18).
Trp-297 was similarly important for exendin-4 and GLP-1(7–
36)-NH2 (18) and a prerequisite for cAMP signaling at the
weaker agonist peptides. Arg-299, Asn-302, and Cys-296 were
important for maintaining oxyntomodulin and GLP-1(7–36)-
NH2 (18) bias for cAMP over pERK1/2 but were less critical for
exendin-4-mediated bias (Table 6 and supplemental Fig. S1).
Mutation ofArg-299 andTyr-305 to alanine also promoted bias
toward pERK1/2 for GLP-1(1–36)-NH2 (18). The N304A
mutation, however, was associated with a preferential loss of
cAMPsignaling over pERK1/2 forGLP-1(7–36)-NH2 andGLP-
1(1–36)-NH2 (18) and to a lesser extent exendin-4, with limited
impact on oxyntomodulin.
DISCUSSION
There is increasing evidence that the ECL2 of family A
GPCRs plays a critical role in activation transition of GPCRs as
well as being an important region for allosteric modulation of
receptors (14, 20–26). In this study, we have used alanine scan-
ning of residues of ECL2 and adjacent amino acids to examine
the role of these residues in binding and signaling mediated by
peptide and nonpeptide ligands of the GLP-1R, a family B
FIGURE 4. Ca2imobilization profiles of humanGLP-1R ECL2 alaninemutants. Characterization of Ca
2
imobilization in the presence of exendin-4 (A and
B) in FlpInCHO cells stably expressing the wild type human GLP-1R or each of the human GLP-1R ECL2 alaninemutants that effect peptide binding affinity (A)
or have no significant effect on peptide binding affinity (B) is shown. Data are normalized to the maximal response elicited by 100 M ATP and analyzed with
an operational model of agonism as defined in Equation 2 of the accompanying article. All values are means S.E. of four to five independent experiments,
conducted in duplicate. Visual representation of Ca2i coupling efficacy (logc) in the presence of exendin-4 (C) is shown. Statistical significance of changes in
coupling efficacy in comparison with wild type human GLP-1R was determined by one-way analysis of variance and Dunnett’s post test, and values are
indicated with an asterisk (*, p 0.05). All values are logc S.E. error of four to five independent experiments, conducted in duplicate. Data presented in D
are levels of Ca2i mobilization in the presence of 1 M oxyntomodulin and are normalized to the maximal response elicited by 100 M ATP. Statistical
significance of changes in response in comparisonwithwild type humanGLP-1Rwas determinedby one-way analysis of variance andDunnett’s post-test, and
values are indicated with an asterisk (*, p 0.05). All values are means S.E. of three to five independent experiments, conducted in duplicate.
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GPCR. Exendin-4 is a high affinity GLP-1 peptide mimetic cur-
rently approved for clinical treatment of type II diabetics (3, 27,
28), although oxyntomodulin is a naturally occurring GLP-1R
peptide ligand with intermediate potency between full-length
and truncated GLP-1 peptides (1, 29). In accord with observa-
tions for GLP-1 peptides in our accompanying article (18),
ECL2 was critically important for activation transition of the
GLP-1R by exendin-4 and oxyntomodulin, albeit with distinc-
tions in the involvement of individual residues. In contrast,
activation of the receptor by the small molecule agonist, com-
pound 2, was relatively unaffected by ECL2 mutations, with
most effects tracking with loss in cell surface receptor expres-
sion. As such, ECL2 appeared to play only a limited role in
compound 2-mediated receptor activation.
As also noted for GLP-1 peptides (18), residues that were
highly conserved across family B peptide hormone receptors
(Lys-288, Asp-293, Cys-296, Trp-297, and Trp-306) were
among thosemost critical for receptor function, demonstrating
marked loss in agonist peptide binding andmarked attenuation
of peptide-mediated signaling.W306Awas not expressed at the
cell surface and consequently could not be examined further.
Of the others, K288A was the most deleterious, and this likely
relates to a critical structural role for this residue for peptide-
mediated actions. We have previously speculated that this may
be involved in stabilization of the top of TM4 by “snorkeling”
(18), whichmay be required for correct orientation of ECL2 for
peptide-mediated receptor activation. Nonetheless, this was not
critical to compound 2-mediated receptor activation, indicating
that this ligand activates the receptor in a unique manner as dis-
cussed below. Although Cys-296 and Trp-297 are highly con-
served and likely to be structurally important for the entire B
receptor subfamily (see Fig. 1A of Ref. 18), they also appear to
contribute to signal bias of high affinity peptide agonists of the
GLP-1R (supplemental Fig. S1). Cys-296 is predicted to form a
disulfide bridge with Cys-226 at the top of TM3 in a similar man-
ner to family AGPCRs (30), providing conformational restriction
on themovementof ECL2.Residuesdistal to this aminoacid likely
contribute to propagation of conformational rearrangement of
TM5 thathas been shown toundergo translationalmovements on
the intracellular face of the receptor for agonist-occupied G pro-
tein-coupled 2-adrenoreceptor (31–33), and this is likely impor-
tant in receptor activation. Consistent with this, residues distal to
Cys-296 generally had a greater impact on receptor signaling.
Comparison of Effect ofHumanGLP-1RECL2AlanineMuta-
tions on Peptide Binding and Function, Exendin-4 Versus
Oxyntomodulin—For mutants at which binding affinity could
robustly be estimated for both peptides, most mutants had
comparable effects on affinity. The exceptions were C296A,
FIGURE 5. Compound 2-mediated cAMP accumulation and pERK1/2 profiles of human GLP-1R ECL2 alanine mutants. Characterization of cAMP accu-
mulation (A andB) andpERK1/2 (C andD) in thepresenceof compound2 in FlpInCHOcells stably expressing thewild typehumanGLP-1Ror eachof thehuman
GLP-1R ECL2 alaninemutants is shown. cAMPaccumulationdata are normalized to the response elicitedby 100M forskolin, andpERK1/2 data are normalized
to themaximal response elicited by 10% FBS, and all data are analyzedwith a three-parameter logistic equation as defined in Equation 1 of the accompanying
article. All values are means S.E. of four to seven independent experiments, conducted in duplicate.
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W297A, R299A, and Y305A, where affinity estimates could not
be determined for oxyntomodulin due to incomplete or poorly
defined curves, and K288A, E292A, and N300A, where there
was greater loss of exendin-4 affinity relative to that of oxynto-
modulin. Each of these was among the most profoundly
affectedmutants for exendin-4 affinity andmay, at least in part,
reflect differences in affinity of the two peptides for active ver-
sus inactive states of the receptor, as discussed below.
Although the effect of ECL2 mutation on peptide-mediated
cAMP formation was generally similar for exendin-4 and oxyn-
tomodulin, three mutations, E292A, C296A, and N300A, had
differential effects for the two peptides. In each case, there was
a greater effect on exendin-4 potency that paralleled the differ-
ential effect on binding affinity between the peptides. At each of
these mutants, however, oxyntomodulin efficacy was reduced
to a greater extent than the equivalent mutation on exendin-4
response, with respect towild type. Nonetheless, the changes to
cAMP signaling likely reflect a mechanistically similar effect
across the two peptides. For these three mutants, the oxynto-
modulin potency and estimates of affinity are equivalent. Oper-
ationally, loss of efficacy is manifested as a collapse of the
potency toward the affinity value of peptides with subsequent
diminution of maximal response. Where changes in agonist
peptide affinity occur, this may be due to decreased ability to
form the active, high affinityARG ternary complex, wherein the
measured affinity collapses to the affinity for the inactive state
receptor (34). Although theremay be direct effects of themuta-
tions on ligand contact and affinity, the data are principally
consistent with decreased ability to formG protein-complexed
receptors.
In contrast, the M303A mutant had distinct effects on the
efficacy of exendin-4 and oxyntomodulin in the absence of
altered potency with selective loss of exendin-4 efficacy. As
described above, this mutant was also an outlier in the correla-
tion analyses of cAMP versus pERK1/2 signaling for both pep-
tides (supplemental Fig. S1). Thus Met-303 appears to play a
distinct role for cAMP formation (and by inference Gs cou-
pling) for these peptides with GLP-1(7–36)-NH2 exhibiting an
intermediate profile (supplemental Fig. S2) (9).
Although operational measures of oxyntomodulin efficacy
forCa2imobilization could not be determined due to theweak
response, comparison of the maximal effect of oxyntomodulin
at 1 M with the responses to exendin-4 revealed apparent dif-
ferences in the effect ofmutation onCa2i signaling for the two
peptides, with preservation of oxyntomodulin responses for
L290A, Y291A, and E294A, and significant loss of exendin-4
signaling. For these mutants, there was no significant decrease
in 125I-exendin(9–39) binding (see Table 1 of Ref. 18) suggest-
ing that therewas a similar level of functional cell surface recep-
tors. Ca2i responses toGLP-1(7–36)-NH2were also decreased
at these four mutants, suggesting that there are differences in
how oxyntomodulin, and the high affinity peptides modulate
Ca2i signaling.
Comparison of Effect of Human GLP-1R ECL2 Alanine Muta-
tions on Peptide Function, Exendin-4 Versus GLP-1(7–36)-NH2—
Exendin-4 and GLP-1(7–36)-NH2 are generally considered to
interact with and activate the receptor in an equivalentmanner,
and indeed, the efficacy of these two peptides for the three
pathways studiedwas very similar (Tables 2–4 of this paper and
Ref. 18). This was also generally reflected in the effect of muta-
tion on the function of the two peptides. Nonetheless, some
subtle differences in responses were observed (supplemental
Fig. S2). In the assay of cAMP formation, all except two of the
mutants had effectively equivalent magnitude of potency alter-
ation (0.5 log unit difference); the exceptionswere R299A and
L307A that exhibited greater loss in potency for GLP-1(7–36)-
NH2 comparedwith exendin-4. The effect on efficacy of the two
peptides was also similar; however, residues after Cys-296 had
greater loss of exendin-4 efficacy relative toGLP-1(7–36)-NH2,
with the exception of N300A that had the opposite effect. This
suggests that translation of exendin-4 signaling toGs coupling
is more reliant on structural conservation of the distal segment
of ECL2.
There was also a strong correlation between the effect of
mutants on exendin-4 and GLP-1(7–36)-NH2 efficacy for
pERK1/2. Nonetheless, the N300A mutant appeared to dis-
criminate between the two peptides, and indeed this was true
for oxyntomodulin and GLP-1(1–36)-NH2 (see Table 3 of
Ref. 18), with a rank order for loss of efficacy of GLP-1(1–
TABLE 5
Effects of human GLP-1R ECL2 alanine mutants on the allosteric ago-
nist compound 2
Datawere analyzedusinga three-parameter logistic equationasdefined inEquation1of
the accompanying article. pEC50 values represent the negative logarithmof the concen-
tration of agonist that produces half the maximal response. E[10 M] in the data repre-
sents the response elicited at 10Mcompound 2, normalized to the response elicited
by 100 M forskolin (cAMP) or 10% FBS (pERK1/2). Values are expressed as
means  S.E. of four to seven independent experiments, conducted in duplicate.
Data were analyzed with one-way analysis of variance and Dunnett’s post test. Gray
shading highlights residues effecting peptide agonist binding affinity. ND indicate
data unable to be experimentally defined.
* Data are statistically significant at p 0.05, one-way analysis of variance, and
Dunnett’s post test in comparison with wild type response.
† Profiles deviate from wild type, but pIC50 and/or pEC50 values for this ligand
were unable to be determined in concentration range tested.
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36)-NH2  oxyntomodulin  GLP-1(7–36)-NH2  exen-
din-4. As described above, the Asn-300 residue is also linked
to signal bias of peptides between cAMP and pERK1/2 for
exendin-4, GLP-1(7–36)-NH2, and oxyntomodulin and sug-
gests that it makes critical intra-receptor interactions that
underlie this effect.
Although the efficacy for exendin-4 and GLP-1(7–36)-NH2
was similar at the wild type receptor in Ca2i signaling (logc
0.70  0.07 and 0.63  0.08 (18), respectively), there was
greater relative loss of exendin-4 Ca2i signaling withmutation
of ECL2. This was manifest as virtual abolishment of exendin-
4-mediated responses for E293A, R299A, Y305A, and L307A,
although reduced but measurable responses were observed
with GLP-1(7–36)-NH2 (18). This differential effect on Ca2i
may be due to differences in the mechanism of receptor cou-
pling to Ca2i signaling for the two peptides; exendin-4 signal-
ing was relatively insensitive to pertussis toxin pretreatment
(reduced 28.7  8.3%), whereas the GLP-1(7–36)-NH2
response was attenuated by 37.0 7.1% (supplemental Fig. S3)
indicating that Gi/o proteins play a greater role in GLP-1(7–
36)-NH2 signaling linked to Ca2i mobilization. Although not
conclusive, the Gi/o response may be less dependent upon
conformational propagation through ECL2.
Generically, the inability to couple to Ca2 in the cases of
K288A, E292A, D293A, C296A, W297A, R299A, Y305A, and
L307A in the presence of exendin-4 was also reflected in severe
impairment to couple to the cAMP pathway, suggesting that
these residues are perhaps not important in pathway selectivity
between cAMP and Ca2. However, receptor mutants C296A,
R299A, and Y305A all demonstrated increased ability to couple
to pERK1/2 despite no detectable signaling through the Ca2i
pathway, suggesting some involvement in pathway selectivity at
these residues. Additionally, although N302A and M303A had
some ability to couple to the Ca2i pathway when activated by
exendin-4, it was noted that these were two of themost severely
impairedmutant receptors in cAMP coupling but also only had
small reductions in pERK1/2 coupling, which may indicate
importance in pathway selectivity at these residues. These
results suggest that ECL2 has a greater influence on Ca2i acti-
vation by exendin-4 than other signaling pathways.
Collectively, the data suggest that exendin-4 and GLP-1(7–
36)-NH2 likely activate the receptor via subtly different mech-
FIGURE6.Correlationplots ofpathwayefficacy (logc) of humanGLP-1RECL2alaninemutants.Correlationplots of changes inpathway coupling efficacy
(logc) of human GLP-1R ECL2 alanine mutants with respect to wild type receptor are shown. A, pERK1/2 versus cAMP for exendin-4; B, Ca
2
i versus cAMP for
exendin-4; C, pERK1/2 versus Ca2i for exendin-4; andD, pERK1/2 versus cAMP for oxyntomodulin. Datawere fit by linear regression. The line of regression and
99% confidence intervals (—) are displayed.
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anisms, and this may have implications for their use as thera-
peutic agents. Indeed, the evidence for differentmechanisms of
activity is also seenwithmutation of Lys-288 at the rat GLP-1R,
with significantly greater decreases in binding affinity of GLP-
1(7–36)-NH2 than exendin-4 (13). Furthermore, the affinity of
GLP-1(7–36)-NH2 is highly sensitive toN-terminal truncation,
whereas exendin-4 is not; exendin-4 can be truncated by up to
eight residues without significant loss of binding affinity for the
GLP-1R (35). In addition, despite identical homology in the
N-terminal seven residues, GLP-1(9–36)-NH2 is a partial ago-
nist, although exendin(3–39) is an antagonist (35). Although
this is most likely a composite of both N- and C-terminal pep-
tide interactions with the receptor, these differences in GLP-1
and exendin-4 binding and function are supportive of differen-
tial mechanisms of activation at the GLP-1R (36–38).
Distinct Receptor Activation Mechanisms for Peptide and
SmallMoleculeAgonists—In contrast to the dramatic effects on
peptide-mediated binding and signaling,mutation of ECL2 res-
idues had limited impact on activation of the receptor by the
small molecule agonist compound 2. In the cases where there
TABLE 6
Effects of human GLP-1R ECL2 alanine mutants on exendin-4- and oxyntomodulin-mediated signaling bias
Data were analyzed using an operational model of agonism as defined in Equation 4 of the accompanying article to estimate logc/KA ratios. Changes in logc/KA ratios with
respect to wild type were used to quantitate bias between signaling pathways. Values are expressed as means S.E. of three to seven independent experiments, conducted
in duplicate. Data were analyzed with one-way analysis of variance and Dunnett’s post test. Gray shading highlights residues effecting peptide agonist binding affinity. ND
indicates data unable to be experimentally defined.
* Data are statistically significant at p 0.05, one-way analysis of variance, and Dunnett’s post test in comparison with wild type response.
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was a reduction in cAMP Emax, there was a parallel loss in func-
tional receptors at the cell surface that may account for the
effect of these mutations. Likewise, there was little effect on
signal bias for compound 2 across the mutants, with observed
alterations paralleling loss of cAMPsignaling that accompanied
lower functional cell surface receptor expression (supplemental
Fig. S1E). A similar distinction in effect on peptide versus small
molecule activation of the receptorwas seen for the inactivating
polymorphic variant Met-149, which selectively attenuated
GLP-1(7–36)-NH2 and exendin-4, but not compound 2 signal-
ing (9). At this variant, compound 2 could also allosterically
rescue peptide activation of the receptor (9). Collectively, these
data provide evidence for distinct modes of receptor activation
for peptide and nonpeptide agonists, with peptide-mediated
activation of the receptor critically involving conformational
propagation through ECL2, although compound 2-mediated
activation appears to principally occur independently of this.
The conformational transition leading to interaction with
signaling effectors in response to agonist occupation of the
receptor is thought to involve reorganization of hydrogen
bonding networks within the transmembrane domain of the
receptors leading to marked changes in the intracellular face of
the receptor (31–33). How agonists bind to the receptor to
mediate these effects is still mostly unclear. In this study, we
have provided evidence for a critical role of the ECL2 of the
GLP-1R in propagating this conformational change upon pep-
tide binding, and also for directing signaling bias at this recep-
tor. The data also suggest that individual peptides differentially
influence ECL2 to mediate their effects, although the small
molecule agonist, compound 2, has a distinct mechanism for
receptor activation.
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